Page 1

Announcement no . 9/2021 8 November 2021 Coloplast Ostomy Care Continence Care Wound & Skin Care Interventional Urology Coloplast A / S Holtedam 1 DK - 3050 Humlebaek Denmark Coloplast announces agreement to acquire Atos Medical Coloplast has signed an agreement to acquire Atos Medical , the global market leader in laryngectomy , for EUR 2,155 million ( around DKK 16 billion ) from PAI Partners Company reg . ( CVR ) no . 69749917 Coloplast has signed an agreement to acquire Atos Medical , the global market leader in laryngectomy from PAI Partners , a global private equity firm headquartered in Paris . Atos Medical's purpose of making life easier for people living with a neck stoma is closely aligned with Coloplast's purpose of making life easier for people with intimate healthcare needs Atos Medical represents a new long - term growth category for Coloplast operating with its own identity , brand and execution strength while benefitting from the industry leading capabilities and track record of Coloplast to drive continuous growth and value creation Following the expected acquisition , Coloplast gains access to a new chronic care segment to be run as a separate strategic business unit operating on shared Coloplast infrastructure The total purchase price ( enterprise value ) for Atos Medical amounts to EUR 2,155 million ( around DKK 16 billion ) The transaction is expected to be increasingly EPS accretive from 2022 / 23¹ Closing of the transaction is subject to customary regulatory approvals and is anticipated in Q2 2021/22 Atos Medical , with its attractive growth profile and margin structure , presents an attractive new long - term growth opportunity for Coloplast . Atos Medical will benefit from Coloplast's commercial capabilities , as well as financial strength , allowing Atos Medical to continue its strong growth outlook . " As part of our Strive25 strategy , Coloplast is committed to securing future long - term growth drivers through organic and inorganic initiatives . Atos Medical is a purpose - driven chronic care business with a mission that fits perfectly with Coloplast . The strategic and financial logic is compelling . I am truly pleased to welcome a new chronic care business into the family with a strong fit to our chronic commercial model - category leadership through innovation , strong relationships with healthcare professionals and a direct - to - consumer set - up , " says Kris tian Villumsen , President & CEO of Coloplast . " Atos Medical is an undisputed leader in chronic neck stomas care , and we are well - positioned for long - term growth . Our companies have comparable business models , and the acquisition will enable us to leverage Colo plast's strengths to serve more people living with a neck stoma even better than today . Coloplast is a world leading medical device company with an impressive track record . I believe our companies are a great match , and I am confident that together we can accelerate our journey to the benefit of our customers worldwide , " says Britt Meelby Jensen CEO of Atos Medical . 1 ) After integration , transaction and financing costs . " We are proud to have been part of Atos Medical's impressive growth journey under Britt and her team's inspiring leadership . The company's strong organic growth track - record and industry leading margins are a testimony to its unique direct - to - consumer set - up while also being able to do selective M & A in existing and adjacent segments such as tracheostomy . I feel privileged having had the opportunity to work alongside Atos Medical management and its employees on their quest to improve the quality of life of neck stoma patients , " says Ragnar Hellenius , PAI Partners . Atos Medical - the global market leader in laryngectomy Founded in Sweden in 1986 , Atos Medical was born out of a desire to make life easier for people living with a laryngectomy by providing personalised care and innovative solutions for restoring speaking ability after surgical removal of the patients ' voice box . Today , Atos Medical helps improve the lives of patients following both laryn gectomy and tracheostomy procedures . Atos Medical has developed the laryngectomy category and is the leading global company serving this patient group with end - to - end solutions from surgical intervention to lifetime patient care . Laryngectomy is a niche chronic segment with many similarities to Coloplast's existing chronic patient segments . The laryngectomy market remains significantly underserved , also across existing markets , due to patients not being served adequately with products